Şenay Demi̇r

Şenay Demi̇r

Auto-generated profile, based on publicly available information

Şenay Demi̇r

Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Tuberk Toraks
Verified
Journal Article
Open access
GSGurgun Tuğçe Vural Solak
Gurgun Tuğçe Vural Solak
KAKurtuluş Aksu
Kurtuluş Aksu
YSYavuzalp Solak
Yavuzalp Solak
ŞDŞenay Demi̇r
Şenay Demi̇r
DEDilek Çuhadar Erçelebi̇
Dilek Çuhadar Erçelebi̇
SYSelma Yesilkaya
Selma Yesilkaya
The aim of this study was to elucidate the incidence of local, large local and systemic reactions after subcutaneus immunotherapy (SCIT) injections in our clinic and to determine the characteristic features of these adverse reactions. A total of 6000 SCIT injections administered to 163 patients between January 2011 and December 2021 were retrospectively evaluated. The study population consisted of patients with allergic rhinoconjunctivitis who underwent SCIT due to pollen, house dust mite or cat allergy, or patients who underwent SCIT due to venom allergy. Demographic characteristics of the patients, diagnoses, allergen sensitivities, immunotherapy protocol applied, adverse reactions, and the characteristics of these reactions were recorded. Totally, 163 patients with a mean age of 36.8 ± 12.7 years were enrolled in this research. Sex distribution was as follows: 55.2% (n= 90) were females. During the study, 218 allergic reactions were detected in 83 patients. The incidence of adverse reactions per injection was 3.6%. The probability of developing an adverse reaction in a patient during the entire subcutaneous immunotherapy was 53.9%. Of the adverse reactions that developed, 94 (43.1%, n= 47) were observed locally while 56 (25.7%, n= 40) were large local reactions, and 68 (31.2%, n= 30) were systemic. Incidence of adverse reactions per injection were 1.5%, 0.9%, and 1.1% for local reaction, large local reaction, and systemic reaction, respectively. The results of this analysis elaborated that subcutaneous immunotherapy is a safe and tolerable treatment modality. However, before initiating treatment, the benefits and risks should be evaluated. The risk of systemic reactions is quite low, but fatal anaphylaxis can occur, so physicians need to be aware of the potential risks.

8 March 2024 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
GBGözde Köycü Buhari
Gözde Köycü Buhari
SBSakine Nazik Bahçecioğlu
Sakine Nazik Bahçecioğlu
SGSelcan Gültuna
Selcan Gültuna
ÖAÖzgür Akkale
Özgür Akkale
HTHATICE CELIK TUGLU
HATICE CELIK TUGLU
KAKurtuluş Aksu
Kurtuluş Aksu
Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten (25.6%) patients had known other drug allergies and three (7.7%) patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle (n=29, 74.4%). Ten (25.4%) patients had hypersensitivity reactions at the first application of etoposide. Thirty (76.9%) patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 (53.3%) and moderate in 14 (46.7%) patients. Most common symptoms were erythema in 29 (96.7%), dyspnea in 13 (43.3%), chest tightness in 8 (26.7%), discomfortness in 7 (23.3%), and hypertension in 6 (20%). Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 (11.1%) patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

28 July 2023 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
SBSakine Nazi̇k Bahçeci̇oğlu
Sakine Nazi̇k Bahçeci̇oğlu
HAHale Ateş
Hale Ateş
IKİlkay Koca Kalkan
İlkay Koca Kalkan
KAKurtuluş Aksu
Kurtuluş Aksu
ŞDŞenay Demi̇r
Şenay Demi̇r
SYSelma Yesilkaya
Selma Yesilkaya
Aims: Inspiratory particle load including the allergens in the inhaled air is decreased by the use of the mask, which is one of the methods for COVID-19 protection. The aim of the study is to investigate the effect of masks used by seasonal allergic rhinitis patients with pollen allergy on the control of rhinitis symptoms. Methods: Mask usage characteristics of patients (mask type used, average number of days per week for mask usage, daily usage time),whether there was a change in the time spent outdoors during the pandemic compared to the pre-pandemic period, and rhinitis complaints and frequency of rhinitis-related drug use before the pandemic compared to the pandemic period were investigated. Results:The frequency of nasal discharge (6.62±1.69; 6.00±1.89: p<0.001), obstruction (4.56±1.64; 4.28±1.86: p=0.099), itching(7.49±1.55; 7.16±1.83: p=0.038), sneezing (5.54±1.60; 5.21±1.89: p=0.046), and frequency of drug use (5.52±1.62; 5.17±1.91: p=0.037) decreased statistically significantly after the pandemic according to the visual analog scoring. However, an increase was found in ocular symptoms. Conclusion:Although studies with larger patient and control groups are needed, we think that the use of face masks during the COVID-19 pandemic is an effective protective measure for protection from pollen in patients with allergic rhinitis,who have pollen sensitivity.

27 December 2025 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
GSGurgun Tuğçe Vural Solak
Gurgun Tuğçe Vural Solak
KAKurtuluş Aksu
Kurtuluş Aksu
DÇDilek Çuhadar
Dilek Çuhadar
ŞDŞenay Demir
Şenay Demir
ÖGÖzge Göktürk
Özge Göktürk
BUBarış Uslu
Barış Uslu
Aims: Patch testing is a standard procedure in the diagnosis of allergic contact dermatitis. It is based on the principle that the reaction reappears after contact with the allergen. The aim of our study is to evaluate allergen sensitivity in our region and the factors affecting it. Methods: Patients who underwent at least one patch test from the European Baseline Series (EBS), cosmetic series or dental series at our clinic between January 2024 and July 2025 were included in the study. The patients' age, gender, presence of atopy, accompanying allergic diseases, body areas suspected of dermatitis, and patch test results were retrospectively evaluated. Results: Of the 115 patients included in the study, 73.9% were female, with a median age of 45 (min-max: 18-80). In patients undergoing EBS (n=41), nickel (II) sulphate and cobalt (II) chloride were the most frequently detected allergens. In the cosmetic series patch test group (n=55), gallate mix and thimerosal were most frequently detected, while in the dental series patch test group, nickel (II) sulphate and sodium tetrachloropalladate (II) hydrate were predominant. The median age of patients with multiple allergen sensitivities was significantly lower than that of patients with single allergen sensitivities (p=0.005). Conclusion: Our study found that regional allergen sensitivity was consistent with data in the literature. Our study shows that multiple allergen positivity is more common in young patients and emphasises the importance of patch testing in identifying relevant allergens and guiding clinical treatment.

30 September 2022 in Journal of Contemporary Medicine
Verified
Journal Article
Closed access
PDF file
HAHale Ateş
Hale Ateş
IKİlkay Koca Kalkan
İlkay Koca Kalkan
KAKurtuluş Aksu
Kurtuluş Aksu
MTMusa Topel
Musa Topel
SYSelma Yesilkaya
Selma Yesilkaya
SBSakine Nazi̇k Bahçeci̇oğlu
Sakine Nazi̇k Bahçeci̇oğlu
Aim: This study aimed to evaluate the effects of the COVID-19 pandemic on treatment adherence in patients with severe asthma who were receiving omalizumab and mepolizumab treatment in our clinic. Material and Method: A total of 53 patients with severe asthma, 45 of whom were using omalizumab and 8 of whom were using mepolizumab, were included in the study. The medical records of the patients were recorded anonymously and retrospectively. Results: It was seen that the rate of patients using omalizumab in the study population decreased during the pandemic period compared to the 1-year period before the pandemic. It was observed that approximately 51% of the patients using omalizumab missed routine treatment doses. The major factor in skipping treatment doses was the fear of contracting COVID-19 upon admission to the hospital. In the mepolizumab group, the rate of using biologic agents during the pandemic period increased compared to 1 year before the pandemic. Dose skipping was observed among 37.5% of the patients in this group and it was found that the major risk factor for skipping a dose was the fear of contracting COVID-19 upon admission to the hospital. Conclusion: In this study, it was found that there was a decrease in the duration and rate of use of biologic agent therapies administered in a health institution under the supervision of a healthcare professional among patients with severe asthma during the pandemic.